Alector prices $75 million stock offering at $2.05 per share
The neurodegeneration-focused biotech priced an underwritten offering of 36.6 million shares, with closing expected October 19, 2026.
Alector, Inc. announced on October 16, 2026 that it had priced an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock.1 The shares are priced at $2.05 per share, about 7.3% above the stock's closing price on October 15, 2026.1
Alector expects gross proceeds of $75,030,000.00, before underwriting discounts, commissions and other estimated offering costs.1 The company is the seller of all shares in the offering.1 Closing is expected on or about October 19, 2026, pending customary closing conditions.1
New and existing investors taking part in the financing include TCGX, BVF Partners, ADAR1 Capital Management and Deep Track Capital, among others.1 Alector said net proceeds would go toward general corporate purposes, potentially covering research, development, and manufacturing of its product candidates, along with working capital, capital spending, other corporate costs, and possible acquisitions or strategic deals involving complementary products, technologies, or businesses.1
Morgan Stanley & Co. LLC and BTIG, LLC are serving as joint lead book-running managers for the offering.1 The shares are being offered under a shelf registration statement that Alector had previously filed with and had declared effective by the SEC.1
Separately, in its related 8-K filing, Alector disclosed that on October 15, 2026 it entered into an underwriting agreement with Morgan Stanley and BTIG covering the 36,600,000-share sale at $2.05 per share.1 The offering is being conducted under the company's effective Form S-3 registration statement, File No. 333-294241, along with a related prospectus and prospectus supplement filed with the SEC.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.